Ann Partridge receives 2024 ESMO Award for significant contributions to breast cancer research and patient care
The European Society for Medical Oncology (ESMO) recognized Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, as a recipient of the 2024 ESMO Award: Addressing the Unintended Consequences of Cancer Care. The prestigious international award recognizes her work and commitment to the field of breast cancer, which has led to significant advancements in understanding breast cancer and caring for those who develop the disease around the world.
Partridge is the founder and director of the Program for Young Adults with Breast Cancer, director of the Adult Survivorship Program, and the vice chair of medical oncology at Dana-Farber. She holds the Eric P. Winer, MD, chair in breast cancer research.
Her clinical research focuses on improving the care and outcomes of patients with breast cancer, with an emphasis on treatment, survivorship, and psychosocial issues.
The esteemed ESMO Award was established in 1985 to recognize outstanding contributions to the development of medical oncology by promoting it as a specialty within the European and international community.
The 2024 ESMO Award will be presented to Partridge at the ESMO 2024 Opening Session on September 13, 2024, in Barcelona, Spain.
Media Contacts
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.
Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, recieves the 2024 ESMO Award.